Clinical Data Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug PharmaphorumBiogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.NeuroscienceRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: REGENXBIO slumps after serious side effects mar Duchenne gene therapy resultsNext: ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
